Sacituzumab Govitecan drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Trodelvy® |
| INN | Sacituzumab Govitecan |
| API type | Sacituzumab Govitecan is a Trop-2-directed antibody-drug conjugate (ADC). Sacituzumab is a humanised monoclonal antibody (hRS7 IgG1κ) that recognises Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a hydrolysable linker. Approximately 7-8 molecules of SN-38 are attached to each antibody molecule. |
| Pharmacotherapeutic group | Immunosuppressants, selective immunosuppressants. |
| ATC code | L01FX17 |
| Target of antibody | Trop-2 |
| General function | Sacituzumab Govitecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Sacituzumab Govitecan binds to Trop-2-expressing cancer cells and is internalised with the subsequent release of SN-38 from a hydrolysable linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Information not available. |
| Original license holder | Gilead Sciences Ireland UC |
| Marketing authorisation numbers | EU/1/21/1592/001 |
| Marketing authorisation holder | Gilead Sciences Ireland UC Carrigtohill County Cork, T45 DP77 Ireland |
| Name of the manufacturer of the biological active substance | BSP Pharmaceuticals S.p.A. Via Appia km 65,561 04013 Latina Scalo (LT) Italy |
| Name and address of the manufacturer(s) responsible for batch release | Gilead Sciences Ireland UC IDA Business and Technology Park Carrigtohill Co. Cork, T45 DP77 Ireland |
| Max shelf life | 3 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | 2-(N-morpholino)ethane sulfonic acid (MES) Polysorbate 80 (E433) Trehalose dihydrate |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
